Prognosis of ovarian clear cell cancer compared with other epithelial cancer types: A population‑based analysis

Liu,Hong; Xu,Yanbo; Ji,Jiali; Dong,Rongrong; Qiu,Huiqing; Dai,Xiaolan

doi:10.3892/ol.2020.11252

Prognosis of ovarian clear cell cancer compared with other epithelial cancer types: A population‑based analysis

Authors:
- Hong Liu
- Yanbo Xu
- Jiali Ji
- Rongrong Dong
- Huiqing Qiu
- Xiaolan Dai
View Affiliations

Affiliations: Department of Medical Oncology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, P.R. China, Department of Surgical Oncology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, P.R. China, Department of Oncology, Affiliated Cancer Hospital of Nantong University, Nantong, Jiangsu 226000, P.R. China, Department of Medical, The Children's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, P.R. China, Department of Hematology and Medical Oncology, The Second People's Hospital, Quzhou, Zhejiang 324000, P.R. China
Published online on: January 7, 2020 https://doi.org/10.3892/ol.2020.11252
Pages: 1947-1957
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In order to compare the clinicopathological characteristics and survival outcomes of patients with ovarian clear cell carcinoma (CCC) to other epithelial cancer types, a total of 27,290 patients were analyzed, including 2,424 patients with CCC (8.9%), 3,505 patients with endometrioid cancer (EC) (12.8%), 2,379 patients with mucinous cancer (MC) (8.7%) and 18,982 patients with serous cancer (SC) (69.6%). Patients with EC had the most favorable prognosis and patients with SC had the poorest prognosis among all epithelial ovarian cancers. Among patients with stage I cancer, patients with CCC had a more favorable prognosis compared with patients with SC, especially after 60 months (landmark analysis results, HR=2.079, P=0.001) and had a poorer prognosis compared with patients with MC [restricted mean survival time (RMST) difference, ‑3.434 months]. Among patients at stages III and IV, patients with CCC had a poorer prognosis compared with patients with SC (RMST difference in stage III, ‑7.588 months; RMST difference in stage IV, ‑15.445 months) and had a more favorable prognosis compared with patients with MC (RMST difference in stage III, 10.850 months; RMST difference in stage IV, 8.430 months). The present results suggested that most patients with CCC exhibited, high grade, an early stage, unilateral status and were of a young age. In general, patients with SC presented the poorest prognosis among all patients with epithelial ovarian cancer and no significant survival difference was found between patients with CCC and MC. However, after adjusting for stage using pairwise comparisons, the prognosis of patients with CCC was found to be more favorable compared with the patients with SC and worse compared with patients with MC at stage I; the results at stage III‑IV were opposite and the prognosis of patients with CCC was worse compared with the patients with SC and more favorable compared with the patients with MC.

View Figures

View References

1	Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL: Ovarian Cancer Statistics, 2018. CA Cancer J Clin. 68:284–296. 2018. View Article : Google Scholar : PubMed/NCBI
2	Schiller W: Mesonephroma ovarii. Am J Cancer. 35:1–21. 1939.
3	Serov SF, Scully RE and Sobin LH: Histologic Typing of Ovarian Tumors. International histologic classification of tumors. 9. World Health Organization; Geneva: 1973
4	Kennedy AW, Biscotti CV, Hart WR and Webster KD: Ovarian clear cell adenocarcinoma. Gynecol Oncol. 32:342–349. 1989. View Article : Google Scholar : PubMed/NCBI
5	Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tusda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, et al: Clear cell carcinoma of the ovary: A retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer. 94:1369–1374. 2006. View Article : Google Scholar : PubMed/NCBI
6	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistic, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar : PubMed/NCBI
7	Kikuchi Y, Hirata J, Ishii K, Kita and Nagata I: Complexity of cisdiamminedichloroplatinum (II) resistance mechanisms in human ovarian cancer cells. The Mechanism of Cisplatin Resistance and its Circumvention. Nova Science Pub Inc.; New York, NY: pp. 157–174. 1998
8	Tan DS and Kaye S: Ovarian clear cell adenocarcinoma: A continuing enigma. J Clin Pathol. 60:355–360. 2007. View Article : Google Scholar : PubMed/NCBI
9	Jenison EL, Montag AG, Griffiths CT, Welch WR, Lavin PT, Greer J and Knapp RC: Clear cell adenocarcinoma of the ovary: A clinical analysis and comparison with serous carcinoma. Gynecol Oncol. 32:65–71. 1989. View Article : Google Scholar : PubMed/NCBI
10	Kennedy AW, Markman M, Biscotti CV, Emery JD and Rybicki LA: Survival probability in ovarian clear cell adenocarcinoma. Gynecol Oncol. 74:108–114. 1999. View Article : Google Scholar : PubMed/NCBI
11	Yoonessi M, Weldon D, Satchidand SK and Crickard K: Clear cell ovarian adenocarcinoma. J Surg Oncol. 27:289–297. 1984. View Article : Google Scholar : PubMed/NCBI
12	Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I and Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 88:2584–2589. 2000. View Article : Google Scholar : PubMed/NCBI
13	Chan JK, Teoh D, Hu JM, Shin JY, Osann K and Kapp DS: Do clear cell ovarian carcinoma have poorer prognosis compared to other epithelial cell type? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 109:370–376. 2008. View Article : Google Scholar : PubMed/NCBI
14	Rauh-Hain AJ, Winograd D, Growdon WB, Schorge JO, Goodman AK, Boruta DM, Berkowitz RS, Horowitz NS and Del Carmen MG: Prognostic determinants in patients with uterine and ovarian clear cell carcinoma. Gynecol Oncol. 125:376–380. 2012. View Article : Google Scholar : PubMed/NCBI
15	Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M and Terakawa N: Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol. 100:281–7. 2002. View Article : Google Scholar : PubMed/NCBI
16	Alexandre J, Ray-Coquard I, Selle F, Floquet A, Cottu P, Weber B, Falandry C, Lebrun D and Pujade-Lauraine E: GINECO: Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinumpaclitaxel-based chemotherapy, the GINECO experience. Ann Oncol. 21:2377–2381. 2010. View Article : Google Scholar : PubMed/NCBI
17	Nakayama K, Takebayashi Y, Nakayama S, Hata K, Fujiwaki R, Fukumoto M and Miyazaki K: Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin. Cancer Lett. 192:227–235. 2003. View Article : Google Scholar : PubMed/NCBI
18	Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, Hiura M, Nishimura R, Tabata T, Sugiyama T and Kaku T: Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol. 113:331–334. 2009. View Article : Google Scholar : PubMed/NCBI
19	Omura GA, Brady MF, Homsley HD, Yordan E, Major FJ, Buchsbaum HJ and Park RC: Long-term follow-Up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol. 9:1138–1150. 1991. View Article : Google Scholar : PubMed/NCBI
20	Makar AP, Baekelandt M, Troppe CG and Kristensen GB: The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 56:175–180. 1995. View Article : Google Scholar : PubMed/NCBI
21	Cannistra SA: Cancer of the ovary. N Eng J Med. 351:2519–2529. 2004. View Article : Google Scholar
22	Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, et al: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organization for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst. 95:113–125. 2003. View Article : Google Scholar : PubMed/NCBI
23	Oseledchyk A, Leitao MM Jr, Konner J, O'Cearbhaill RE, Zamarin D, Sonoda Y, Gardner GJ, Long Roche K, Aghajanian CA, Grisham RN, et al: Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: A surveillance, epidemiology, and end results cohort study, 2000–2013. Ann Oncol. 28:2985–2993. 2017. View Article : Google Scholar : PubMed/NCBI
24	Rubin SC, Wong GY, Curtin JP, Barakat RR, Hakes TB and Hoskins WJ: Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer following comprehensive surgical staging. Obstet Gynecol. 82:143–147. 1993.PubMed/NCBI
25	Dembo AJ, Bush RS, Beale FA, Bean HA, Pringle JF, Sturgeon J and Reid JG: Ovarian carcinoma: Improved survival following abdominopelvic irradiation in patients with a completed pelvic operation. Am J Obstet Gynecol. 134:793–800. 1979. View Article : Google Scholar : PubMed/NCBI
26	Sorbe B; Swedish-Norgewian Ovarian Cancer Study Group, : Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: A randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer. 13:278–286. 2003. View Article : Google Scholar : PubMed/NCBI
27	Patel SC, Frandsen J, Bhatia S and Gaffney D: Impact on survival with adjuvant radiotherapy for clear cell, mucinous, and endometrioid ovarian cancer: The SEER experience from 2004 to 2011. J Gynecol Oncol. 27:e452016. View Article : Google Scholar : PubMed/NCBI
28	Parker D, Bradley C, Bogle SM, Lay J, Masood M, Hancock AK, Naylor B and Price JJ: Serum albumin and CA125 are powerful predictors of survival in epithelial ovarian cancer. Br J Obstet Gynecol. 101:888–893. 1994. View Article : Google Scholar
29	Fisken J, Leonard RC, Stewart M, Beattie GJ, Sturgeon C, Aspinall L and Roulston JE: The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma. Br J Cancer. 68:140–145. 1993. View Article : Google Scholar : PubMed/NCBI